Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lithium carbonate is a white crystalline inorganic compound used primarily as a mood stabilizer in the treatment and prevention of manic episodes associated with bipolar disorder (manic-depressive illness). It is classified as an antimanic agent. The precise mechanism of action is not fully understood but is believed to involve modulation of neurotransmitter activity and inhibition of enzymes such as inositol monophosphatase and glycogen synthase kinase 3 (GSK-3), which may affect signal transduction pathways in neurons. Lithium alters sodium transport in nerve and muscle cells and shifts intraneuronal metabolism. It has been shown to decrease abnormal activity in the brain associated with mania. Lithium carbonate is also used industrially for glass/ceramic production and other applications[1][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lithium carbonate.